Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130


Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.

Kannan A, Philley JV, Hertweck KL, Ndetan H, Singh KP, Sivakumar S, Wells RB, Vadlamudi RK, Dasgupta S.

Sci Rep. 2019 Aug 12;9(1):11632. doi: 10.1038/s41598-019-48064-w.


EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK.

Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.


Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.

Zhou M, Sareddy GR, Li M, Liu J, Luo Y, Venkata PP, Viswanadhapalli S, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2019 Apr 16;9(1):6124. doi: 10.1038/s41598-019-42313-8.


Neuron-Derived Estrogen Regulates Synaptic Plasticity and Memory.

Lu Y, Sareddy GR, Wang J, Wang R, Li Y, Dong Y, Zhang Q, Liu J, O'Connor JC, Xu J, Vadlamudi RK, Brann DW.

J Neurosci. 2019 Apr 10;39(15):2792-2809. doi: 10.1523/JNEUROSCI.1970-18.2019. Epub 2019 Feb 6.


17β-Estradiol Regulates Microglia Activation and Polarization in the Hippocampus Following Global Cerebral Ischemia.

Thakkar R, Wang R, Wang J, Vadlamudi RK, Brann DW.

Oxid Med Cell Longev. 2018 Apr 18;2018:4248526. doi: 10.1155/2018/4248526. eCollection 2018.


Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.

Liu J, Sareddy GR, Zhou M, Viswanadhapalli S, Li X, Lai Z, Tekmal RR, Brenner A, Vadlamudi RK.

Cancer Res. 2018 Jun 15;78(12):3176-3189. doi: 10.1158/0008-5472.CAN-17-3470. Epub 2018 Apr 16.


Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.

Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.

Cancer Res. 2018 Feb 1;78(3):671-684. doi: 10.1158/0008-5472.CAN-17-1327. Epub 2017 Dec 6.


Novel post-transcriptional and post-translational regulation of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1 determine the fate of breast cancer cells to survive or die.

Onyeagucha B, Subbarayalu P, Abdelfattah N, Rajamanickam S, Timilsina S, Guzman R, Zeballos C, Eedunuri V, Bansal S, Mohammad T, Chen Y, Vadlamudi RK, Rao MK.

Oncotarget. 2017 Sep 12;8(49):85984-85996. doi: 10.18632/oncotarget.20841. eCollection 2017 Oct 17.


Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK.

Elife. 2017 Aug 8;6. pii: e26857. doi: 10.7554/eLife.26857.


Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.

Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Rao Tekmal R, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR.

Oncotarget. 2017 Jul 25;8(30):50002-50014. doi: 10.18632/oncotarget.18442.


PELP1: a key mediator of oestrogen signalling and actions in the brain.

Thakkar R, Sareddy GR, Zhang Q, Wang R, Vadlamudi RK, Brann D.

J Neuroendocrinol. 2018 Feb;30(2). doi: 10.1111/jne.12484. Review.


NADPH oxidase in brain injury and neurodegenerative disorders.

Ma MW, Wang J, Zhang Q, Wang R, Dhandapani KM, Vadlamudi RK, Brann DW.

Mol Neurodegener. 2017 Jan 17;12(1):7. doi: 10.1186/s13024-017-0150-7. Review.


HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.

Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK, Manavathi B.

Cell Oncol (Dordr). 2017 Apr;40(2):133-144. doi: 10.1007/s13402-016-0308-2. Epub 2016 Dec 30.


Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.

Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK.

Oncogene. 2017 Apr 27;36(17):2423-2434. doi: 10.1038/onc.2016.395. Epub 2016 Nov 28.


Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.

Sareddy GR, Li X, Liu J, Viswanadhapalli S, Garcia L, Gruslova A, Cavazos D, Garcia M, Strom AM, Gustafsson JA, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2016 Apr 29;6:24185. doi: 10.1038/srep24185.


PELP1: Structure, biological function and clinical significance.

Sareddy GR, Vadlamudi RK.

Gene. 2016 Jul 1;585(1):128-134. doi: 10.1016/j.gene.2016.03.017. Epub 2016 Mar 18. Review.


Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis.

Rajamanickam S, Panneerdoss S, Gorthi A, Timilsina S, Onyeagucha B, Kovalskyy D, Ivanov D, Hanes MA, Vadlamudi RK, Chen Y, Bishop AJ, Arbiser JL, Rao MK.

Clin Cancer Res. 2016 Jul 15;22(14):3524-36. doi: 10.1158/1078-0432.CCR-15-2535. Epub 2016 Feb 29.


Proline-, glutamic acid-, and leucine-rich protein 1 mediates estrogen rapid signaling and neuroprotection in the brain.

Sareddy GR, Zhang Q, Wang R, Scott E, Zou Y, O'Connor JC, Chen Y, Dong Y, Vadlamudi RK, Brann D.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):E6673-82. doi: 10.1073/pnas.1516729112. Epub 2015 Nov 16.


Cancer therapy using natural ligands that target estrogen receptor beta.

Sareddy GR, Vadlamudi RK.

Chin J Nat Med. 2015 Nov;13(11):801-807. doi: 10.1016/S1875-5364(15)30083-2. Review.


Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.

Dang DN, Raj G, Sarode V, Molberg KH, Vadlamudi RK, Peng Y.

Hum Pathol. 2015 Dec;46(12):1829-35. doi: 10.1016/j.humpath.2015.07.023. Epub 2015 Aug 12.


Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy.

Satsangi A, Roy SS, Satsangi RK, Tolcher AW, Vadlamudi RK, Goins B, Ong JL.

Biomaterials. 2015 Aug;59:88-101. doi: 10.1016/j.biomaterials.2015.03.039. Epub 2015 May 15.


Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.

Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK.

Breast Cancer Res Treat. 2015 Apr;150(3):487-99. doi: 10.1007/s10549-015-3339-x. Epub 2015 Mar 19.


PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Cortez V, Samayoa C, Zamora A, Martinez L, Tekmal RR, Vadlamudi RK.

Cancer Res. 2014 Dec 15;74(24):7395-405. doi: 10.1158/0008-5472.CAN-14-0993. Epub 2014 Nov 6.


Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells.

Satsangi A, Roy SS, Satsangi RK, Vadlamudi RK, Ong JL.

Mol Pharm. 2014 Jun 2;11(6):1906-18. doi: 10.1021/mp500128k. Epub 2014 May 21.


Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response.

Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK.

Cell Death Differ. 2014 Sep;21(9):1409-18. doi: 10.1038/cdd.2014.55. Epub 2014 May 2.


Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Gonugunta VK, Sareddy GR, Krishnan SR, Cortez V, Roy SS, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2014 Jun;13(6):1578-88. doi: 10.1158/1535-7163.MCT-13-0877. Epub 2014 Mar 31.


Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.

Zhang QG, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, Vadlamudi RK, Brann DW.

Mol Cell Endocrinol. 2014 May 25;389(1-2):84-91. doi: 10.1016/j.mce.2013.12.019. Epub 2014 Feb 6.


Premature menopause and risk of neurological disease: basic mechanisms and clinical implications.

Scott EL, Zhang QG, Vadlamudi RK, Brann DW.

Mol Cell Endocrinol. 2014 May 25;389(1-2):2-6. doi: 10.1016/j.mce.2014.01.013. Epub 2014 Jan 22. Review.


Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.

Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, Tekmal RR, Vadlamudi RK.

Oncogene. 2014 Jul 10;33(28):3707-16. doi: 10.1038/onc.2013.332. Epub 2013 Aug 26.


Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause.

Zhang QG, Wang RM, Scott E, Han D, Dong Y, Tu JY, Yang F, Reddy Sareddy G, Vadlamudi RK, Brann DW.

Brain. 2013 May;136(Pt 5):1432-45. doi: 10.1093/brain/awt046. Epub 2013 Mar 9.


Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization.

Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen HI, Chang YF, Panneerdoss S, Zoghi B, Buddavarapu KC, Broaddus R, Hornsby P, Tomlinson G, Dome J, Vadlamudi RK, Pertsemlidis A, Chen Y, Rao MK.

PLoS One. 2012;7(12):e52397. doi: 10.1371/journal.pone.0052397. Epub 2012 Dec 21.


KDM1 is a novel therapeutic target for the treatment of gliomas.

Sareddy GR, Nair BC, Krishnan SK, Gonugunta VK, Zhang QG, Suzuki T, Miyata N, Brenner AJ, Brann DW, Vadlamudi RK.

Oncotarget. 2013 Jan;4(1):18-28.


Five friends of methylated chromatin target of protein-arginine-methyltransferase[prmt]-1 (chtop), a complex linking arginine methylation to desumoylation.

Fanis P, Gillemans N, Aghajanirefah A, Pourfarzad F, Demmers J, Esteghamat F, Vadlamudi RK, Grosveld F, Philipsen S, van Dijk TB.

Mol Cell Proteomics. 2012 Nov;11(11):1263-73. doi: 10.1074/mcp.M112.017194. Epub 2012 Aug 7.


Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.

Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK.

Breast Cancer Res. 2012 Jul 19;14(4):R108. doi: 10.1186/bcr3229. Erratum in: Breast Cancer Res. 2012;14(6):404.


Therapeutic significance of estrogen receptor β agonists in gliomas.

Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2012 May;11(5):1174-82. doi: 10.1158/1535-7163.MCT-11-0960. Epub 2012 Mar 21.


Emerging significance of estrogen cancer coregulator signaling in breast cancer.

Mann M, Krishnan S, Vadlamudi RK.

Minerva Ginecol. 2012 Feb;64(1):75-88. Review.


Role of estrogen receptor signaling in breast cancer metastasis.

Saha Roy S, Vadlamudi RK.

Int J Breast Cancer. 2012;2012:654698. doi: 10.1155/2012/654698. Epub 2011 Dec 19.


Significance of PELP1 in ER-negative breast cancer metastasis.

Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L, Vadlamudi RK.

Mol Cancer Res. 2012 Jan;10(1):25-33. doi: 10.1158/1541-7786.MCR-11-0456. Epub 2011 Nov 15.


Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice.

Nair HB, Perla RP, Kirma NB, Krishnegowda NK, Ganapathy M, Rajhans R, Nair SS, Saikumar P, Vadlamudi RK, Tekmal RR.

Horm Cancer. 2012 Apr;3(1-2):26-36. doi: 10.1007/s12672-011-0083-5.


Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.

Nair BC, Vallabhaneni S, Tekmal RR, Vadlamudi RK.

Breast Cancer Res. 2011 Aug 11;13(3):R80. doi: 10.1186/bcr2929.


Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.

Mann M, Cortez V, Vadlamudi RK.

Cancers (Basel). 2011 Mar 29;3(3):1691-707. doi: 10.3390/cancers3021691.


C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection.

Zhang QG, Han D, Wang RM, Dong Y, Yang F, Vadlamudi RK, Brann DW.

Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):E617-24. doi: 10.1073/pnas.1104391108. Epub 2011 Aug 1.


Regulation of rDNA transcription by proto-oncogene PELP1.

Gonugunta VK, Nair BC, Rajhans R, Sareddy GR, Nair SS, Vadlamudi RK.

PLoS One. 2011;6(6):e21095. doi: 10.1371/journal.pone.0021095. Epub 2011 Jun 13.


Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.

Nair HB, Kirma NB, Ganapathy M, Vadlamudi RK, Tekmal RR.

Steroids. 2011 Jul;76(8):792-6. doi: 10.1016/j.steroids.2011.02.038. Epub 2011 Apr 6.


Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.

Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK.

Clin Cancer Res. 2011 Apr 15;17(8):2250-9. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18. Erratum in: Clin Cancer Res. 2013 Mar 1;19(5):1305.


Integrin-linked kinase 1: role in hormonal cancer progression.

Cortez V, Nair BC, Chakravarty D, Vadlamudi RK.

Front Biosci (Schol Ed). 2011 Jan 1;3:788-96. Review.


Significance of ER-Src axis in hormonal therapy resistance.

Vallabhaneni S, Nair BC, Cortez V, Challa R, Chakravarty D, Tekmal RR, Vadlamudi RK.

Breast Cancer Res Treat. 2011 Nov;130(2):377-85. doi: 10.1007/s10549-010-1312-2. Epub 2010 Dec 24.


Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.

Cortez V, Mann M, Brann DW, Vadlamudi RK.

Minerva Ginecol. 2010 Dec;62(6):573-83. Review.


Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.

Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, Kumar R, Tekmal RR, Vadlamudi RK.

Cancer Res. 2010 Sep 15;70(18):7166-75. doi: 10.1158/0008-5472.CAN-10-0628. Epub 2010 Aug 31.


B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.

Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, Bahar R, Kious MJ, Livi CB, Wall SR, Chen L, Zhang B, Shin T, Curiel TJ.

J Immunol. 2010 Sep 1;185(5):2747-53. doi: 10.4049/jimmunol.1000496. Epub 2010 Aug 4.

Supplemental Content

Loading ...
Support Center